



STATUS DECISION OF CONTROLLED AND NON-CONTROLLED SUBSTANCE(S)

Substance: Aripiprazole

Based on the current information available to the Office of Controlled Substances, it appears that the above substance is:

Controlled [ ]
Not Controlled [x]

under the schedules of the Controlled Drugs and Substances Act (CDSA) for the following reason(s):

- The substance is an atypical antipsychotic drug and is not similar in structure to any of the substances in the CDSA.

Prepared by: Evelyn Soo Date: July 29th 2010

Verified by: Marianne Tang Date:

Approved by: DIRECTOR, OFFICE OF CONTROLLED SUBSTANCES Date:

This status was requested by: "third party information removed as per agreement with applicant"

## Drug Status Report


**Drug:** Aripiprazole

**Drug Name Status:** Aripiprazole is the common name.

**Chemical Name:** 7-(4-(4-(2,3-Dichlorophenyl)-1-piperazinyl)butoxy)-3,4-dihydro-2(1H)-quinolinone

**Other Names:** 7-(4-(4-(2,3-Dichlorophenyl)-1-piperazinyl)butoxy)-3,4-dihydrocarbostyryl; abilify, abilitat, discmelt

**Chemical structure:**



**Molecular Formula:** C<sub>23</sub>H<sub>27</sub>Cl<sub>2</sub>N<sub>3</sub>O<sub>2</sub>

**Pharmacological class / Application:** antipsychotic

**CAS-RN:** 129722-12-9

**International status:**

US: The substance is not listed specifically in the CSA and is not mentioned anywhere on the DEA website.

United Nations: The substance is not listed on the Yellow List - List of Narcotic Drugs under International Control nor the Green List - List of Psychotropic Substances under International Control.

Canadian Status: Aripiprazole is considered to be an atypical or second-generation antipsychotic drug and has been shown to be effective in the treatment of psychotic conditions such as schizophrenia<sup>1</sup> and bipolar disorder<sup>2</sup>. Aripiprazole is not listed specifically in the CDSA and is not structurally similar to any of the substances listed in the Schedules to the CDSA.

---

<sup>1</sup>Stip, E. and Tourjman, V. (2010) Aripiprazole in schizophrenia and schizoaffective disorder: a review, *Clin. Ther.* **32**. Suppl. 1: S3-S20.

<sup>2</sup>Fountoulakis, KN. *et al.* (2009) Treatment of psychotic symptoms in bipolar disorder with aripiprazole monotherapy: A meta-analysis, *Ann. Gen. Psychiatry*, **8**: Art no 27.

**Recommendation:** Aripiprazole is not included in any of the schedules to the CDSA and is not a controlled substance.

**Date:** 29 July 2010